Coherus Oncology, Inc. (CHRS) earnings
CHRS earnings moved a median of -2.29% by the close. Quarterly and annual CHRS reports and results, each read against the price at its own news timestamp. Back to the CHRS overview →
32 measured CHRS earnings events.
Where these CHRS earnings landedvs 32 measured CHRS earnings reactions
| Middle 50% of CHRS earnings reactions | -6.72% to 0.00% |
|---|---|
| Median reaction (to close) | -2.29% |
| Measured reactions | 32 |
Point-in-time · zero look-ahead
Half of the 32 CHRS earnings events with a measured close landed between -6.72% and +0.00%; 22% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | +3.99% | -8.33% | |
| Form 10-Q Coherus Oncology, Inc. For: Jun 30 | SEC filing · Form 10-Q | +3.99% | -8.33% | |
| Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026 | Press release | +0.00% | -0.35% | |
| Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | +0.51% | -2.29% | |
| Form 10-Q Coherus Oncology, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.51% | -2.29% | |
| Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026 | Press release | +1.40% | -2.81% | |
| Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update | Press release | +0.54% | +4.84% | |
| Form 10-K Coherus Oncology, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.54% | +4.84% | |
| Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026 | Press release | +1.88% | +3.13% | |
| Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | -0.74% | -0.74% | |
| Form 10-Q Coherus Oncology, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.74% | -0.74% | |
| Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 | Press release | -1.16% | -1.73% | |
| Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | +1.95% | -6.08% | |
| Form 10-Q Coherus Oncology, Inc. For: Jun 30 | SEC filing · Form 10-Q | +1.95% | -6.08% | |
| Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 | Press release | -0.23% | -6.62% | |
| Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | +1.72% | -4.06% | |
| Form 10-Q Coherus BioSciences, For: Mar 31 | SEC filing · Form 10-Q | +1.72% | -4.06% | |
| Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 | Press release | -1.00% | -7.01% | |
| Form 10-K Coherus BioSciences, For: Dec 31 | SEC filing · Form 10-K | -2.54% | -4.57% | |
| Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | +4.13% | +3.03% | |
| Form 10-Q Coherus BioSciences, For: Sep 30 | SEC filing · Form 10-Q | +4.13% | +3.03% | |
| Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024 | Press release | -1.60% | +0.00% | |
| Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | +0.69% | -1.38% | |
| Form 10-Q Coherus BioSciences, For: Jun 30 | SEC filing · Form 10-Q | +0.69% | -1.38% | |
| Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024 | Press release | -0.65% | -7.14% | |
| Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update | Press release | -8.76% | -12.44% | |
| Form 10-Q Coherus BioSciences, For: Mar 31 | SEC filing · Form 10-Q | -8.76% | -12.44% | |
| Coherus to Report First Quarter 2024 Financial Results on May 9, 2024 | Press release | -0.71% | +2.36% | |
| Form 10-K Coherus BioSciences, For: Dec 31 | SEC filing · Form 10-K | -0.68% | +0.00% | |
| Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights | Press release | -7.59% | -8.52% | |
| Form 10-Q Coherus BioSciences, For: Sep 30 | SEC filing · Form 10-Q | -7.59% | -8.52% | |
| Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023 | Press release | +0.96% | +17.54% |
Keep exploring
More CHRS: analyst actions → · SEC filings → · CHRS overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares (CANF) | 278 | -0.48% | 36% |
| AtriCure, Inc. (ATRC) | 276 | +0.04% | 51% |
| Xenon Pharmaceuticals Inc. - Common Shares (XENE) | 276 | +0.03% | 50% |
| Aclaris Therapeutics, Inc. (ACRS) | 275 | 0.00% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.